- About Us
- Drug Discovery
- Regenerative Medicine
- News & Events
- Contact Us
About Us > Management Team
Yossi Ben-Yossef - CEO
Mr. Ben-Yossef co-founded Kadimastem in 2009, along with Prof. Michel Revel. Prior to Kadimastem, he has been leading investments and taking an active role in successful Biotech/Life Sciences companies in the last 12 years. Among the companies he was involved with are Evogen (TASE: EVGN), VBL (NASDAQ:VBLT), and Biondvax (TASE: BNDX).
Prof. Michel Revel, MD, PhD - Chief Scientist
Prof. Revel is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. His research on Interferon, its mechanisms of action and the isolation of the human Interferon-beta gene, have led to the development of Interferon-beta therapy for the treatment of multiple sclerosis, Rebif®, Blockbuster drug marketed worldwide.
In recent years, Prof. Revel's laboratory focused on hESC and succeeded to produce nerve myelinating cells that, when transplanted in myelin-deficient animals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin-producing pancreatic beta cells and nerve myelinating cells.
Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and served as chairman of the Israel National Bioethics Council, and was a member of the International Bioethics Committee of UNESCO.
Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel's National Committee for Biotechnology, serving for three years as its chairman.
Arik Hasson, PhD - Executive VP Research and Development
Dr. Hasson was Kadimastem ’s first employee when it was founded in fall of 2009. Prior to Kadimastem, Dr. Hasson was the head of Stem Cell Projects in Gamida Cell, a stem cell therapeutic company. While at Gamida Cell, Dr. Hasson also headed the diabetic and neurological projects.
Yehuda Feinberg - Chief Financial Officer
Yehuda Feinberg has over 20 years of financial and operational management experience in the biotech, high-tech and telecom sectors, both in startup companies and in large, established companies. Mr. Feinberg has worked with several startup companies in financial managment positions as well as in a consultancy capacity in business planning and financial modeling. Mr. Feinberg served as VP Finance for Rosetta Genomics Ltd. (NASDAQ:ROSG), a biotech startup company and for Roqiya Networks, a hi-tech startup in the field of free-space optical communications. Between 2006 and 2010 Mr. Feinberg served as Corporate Director of Financial Planning and Analysis for NICE Systems Ltd.( NASDAQ: NICE), a leading global hi-tech company. Previously Mr. Feinberg served as Director of Economics and Budgets at Pelephone Communications, Israel's first cellular operator. Mr. Feinberg has a BA in Economics from Rutgers University and an MBA from the Hebrew University of Jerusalem.
Neta Lavon, PhD - Vice president of Operations